All In Biotech

BLA 022175 · Digestive Care INC

Pertzye

Pancrelipase (Amylase, Lipase, Protease) · Oral

Last checked: Nov 20, 2026Latest source record: Feb 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

May 17, 2012

Approved uses

1

Original approval plus efficacy supplements

Registered trials

n/a

n/a Phase 3, n/a recruiting

FAERS reports

3,036

2,620 serious, 297 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 11, 2024.

PERTZYE ® is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. PERTZYE ® is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. ( 1 )

Mechanism: Pancreatic enzyme products contain a mixture of lipases, proteases, and amylases that catalyze the hydrolysis of fats to monoglyceride, glycerol and free fatty acids, proteins into peptides and amino acids, and starches into dextrins and short chain sugars such as maltose and maltotriose in the duodenum and proximal small intestine, thereby acting like digestive enzymes physiologically secreted by the pancreas.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • PERTZYE · PANCRELIPASE (AMYLASE 90,750USP UNITS; LIPASE 24,000USP UNITS; PROTEASE) 86,250USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
  • PERTZYE · PANCRELIPASE (AMYLASE 60,500USP UNITS; LIPASE 16,000USP UNITS; PROTEASE) 57,500USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
  • PERTZYE · PANCRELIPASE (AMYLASE 15,125USP UNITS; LIPASE 4,000USP UNITS; PROTEASE) 14,375USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
  • PERTZYE · PANCRELIPASE (AMYLASE 30,250USP UNITS; LIPASE 8,000USP UNITS; PROTEASE) 28,750USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pancrelipase (Amylase" as an intervention, any sponsor and status, largest first.

All n/a trials
ClinicalTrials.gov returned an error (400). The numbers below may be missing or incomplete.

No registered drug trials name this ingredient.

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea262
  • nausea173
  • dyspnoea148
  • fatigue144
  • infective pulmonary exacerbation of cystic fibrosis137
  • off label use134
  • vomiting132
  • pneumonia130
  • abdominal pain122
  • cough120
  • pyrexia120
  • asthenia117

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200422
200516
200610
200713
200812
200921
201045
201149
201251
201365
201462
2015101
2016123
2017121
2018189
2019297
2020278
2021259
2022297
2023293
2024295
2025277
2026140

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Pertzye (Lipase/Protease/Amylase)

2024 spending

$6.6M

Beneficiaries

382

1,733 claims

Per beneficiary

$17,200

$6.75 per unit

View as table
YearSpending
2020$3,598,177
2021$4,579,812
2022$5,484,305
2023$6,564,873
2024$6,570,457

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1 on PubMed

Sponsor: Digestive Care INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.